Source: https://www.fortunebusinessinsights.com/intra-abdominal-pressure-measurement-devices-market-116080
According to Fortune Business Insights, the global intra abdominal pressure (IAP) measurement devices market was valued at USD 191.6 million in 2025 and is projected to expand from USD 205.3 million in 2026 to USD 332.7 million by 2034, registering a CAGR of 6.2% during the forecast period. North America held the dominant position, capturing a 31% market share in 2025.
These devices measure pressure within the abdominal cavity and are primarily used for diagnosing and managing intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS). Their application is most prevalent in intensive care, trauma, and post-surgical settings, where prompt pressure monitoring directly influences clinical outcomes.
The market is witnessing a prominent shift toward disposable-centric monitoring models. Hospitals increasingly prefer single-use sterile kits for their simplicity, reduced reprocessing requirements, and alignment with infection control protocols in critical care environments. As serial measurements become more routine in high-risk patients, consumable pull-through strengthens, even as capital equipment demand remains relatively stable. There is also a broader transition toward integrated critical care surveillance frameworks, where IAP monitoring is positioned as a standard component rather than a niche standalone intervention.
The primary growth driver is the rising burden of critically ill and post-operative patients susceptible to elevated abdominal pressure — including those with sepsis, major abdominal trauma, pancreatitis, fluid overload, or complex abdominal surgeries. Guidance from the World Society of the Abdominal Compartment Syndrome has reinforced the value of structured bladder-based pressure measurement as a reference standard. As hospitals increasingly standardize critical care pathways, routine device adoption in high-acuity units is becoming more common.
The market faces constraints due to inconsistent protocolization across hospitals and regions. In many facilities, IAP monitoring is used selectively based on physician preference or local ICU culture rather than systematic protocols. The inherently narrow clinical use case — limited to defined high-risk patient populations — restricts broader market scale. Budget pressures in emerging economies and low prioritization in smaller institutions further limit equipment adoption.
A significant opportunity lies in expanding IAP monitoring protocols into mid-tier hospitals, surgical centers, and secondary care settings, particularly across Asia Pacific, Latin America, and the Middle East & Africa, where hospital infrastructure is growing. Education-led adoption initiatives and the availability of user-friendly, cost-effective disposable kits can support broader clinical diffusion beyond specialized tertiary centers.
Growth depends heavily on whether clinicians actively recognize elevated IAP as a condition requiring structured measurement. In many hospitals, it still competes with broader critical care priorities, creating uneven awareness and adoption rates.
The market is segmented by:
Key players leading the market include ConvaTec Group plc, Accuryn Medical, Sentinel Medical Technologies, and Spiegelberg GmbH & Co. KG. These companies hold the largest market shares, driven by strategic product launches, collaborations, and partnerships. In February 2024, ConvaTec launched its next-generation IAP Monitoring System, underscoring ongoing innovation in the space.
Report ID: FBI116080 | Last Updated: May 11, 2026 | Fortune Business Insights